The latest analyst update for Pacific Biosciences of California cuts the rating to Underweight and trims the price target from US$2 to US$1.50, while keeping a fair value estimate of US$2.43 per share ...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...

Pacific Biosciences of California is back in focus after analysts cut their price target to $1.50 from $2, while a separate fair value estimate was trimmed to $2.43 from $2.50. This shift is tied to ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that Basecamp Research has ...

(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to ...

PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi ...

MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year ...

MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...

PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research ...